Trial Profile
Pilot Study of the Efficacy and Safety of Sirolimus in the Treatment of Congenital Hyperinsulinism.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Hyperinsulinaemia
- Focus Therapeutic Use
- 12 Jun 2018 Planned initiation date changed from 1 Aug 2015 to 12 Aug 2015.
- 12 Jun 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 12 Jun 2018 Planned End Date changed from 1 Jun 2018 to 29 May 2018.